Caris lands largest NASDAQ IPO in two years: Finance Report

While the IPO window is far from open, two companies managed to debut on NASDAQ this week.

Caris Life Sciences Inc. (NASDAQ:CAI) raised $494 million through the sale of 23.5 million shares at $21 in what is the largest biopharma IPO of the year. The molecular analysis company had already raised its target range to $19-$20 from $16-$18 ahead of the listing. Last year, the company reported $412.3 million in revenue from its molecular profiling and pharma R&D services units...